Aurobindo Pharma shares: Aurobindo Pharma reported a marginal 0.4% YoY dip in Q4FY25 PAT to Rs 903 crore, even as revenue rose 10.6% to Rs 8,382 crore. For FY25, PAT rose 10% to Rs 3,484 crore. The company highlighted strong volume-led growth, record sales, and robust performance in its European operations.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets